Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) held its 2025 Annual Meeting of Shareholders on Wednesday. The company reported that 72,075,729 common shares, representing approximately 94.10% of its total shares eligible to vote, participated in the meeting. The shareholders voted on four proposals, as outlined in the company’s Proxy Statement.
The first proposal involved the election of directors. The nominees elected to serve until the 2026 annual meeting are Dawn Svoronos, Gillian Cannon, Steven Gannon, Elizabeth Garofalo, Justin Gover, Patrick Machado, Ian Mortimer, and Gary Patou. Each director received a majority of votes in favor.
The second proposal was an advisory vote on the compensation of the company’s named executive officers, commonly referred to as "Say-on-Pay." This proposal was approved with 67,252,200 votes in favor, 2,125,675 against, and 459,935 abstentions.
The third proposal concerned the appointment of PricewaterhouseCoopers LLP as Xenon Pharmaceuticals’ independent registered public accounting firm for the upcoming year. This appointment was approved with 72,041,362 votes for and 34,367 votes withheld.
The final proposal authorized the audit committee of the Board to set the remuneration of the auditor for the ensuing year. This was approved with 72,040,092 votes in favor, 24,835 against, and 10,802 abstentions.
The information is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.